Ditchcarbon
  • Contact
  1. Organizations
  2. Neuraxpharm
Public Profile
Pharmaceutical Preparation Manufacturing
ES
updated 25 days ago

Neuraxpharm

Company website

Neuraxpharm, a leading pharmaceutical company headquartered in Spain, is renowned for its commitment to improving the lives of patients with central nervous system (CNS) disorders. Founded in 1985, the company has established a strong presence across Europe, focusing on the development and distribution of innovative treatments for mental health conditions, including depression and anxiety. With a diverse portfolio of products, Neuraxpharm stands out for its specialised formulations and patient-centric approach. The company has achieved significant milestones, including strategic acquisitions that have expanded its market reach and enhanced its product offerings. As a trusted name in the pharmaceutical industry, Neuraxpharm continues to prioritise research and development, solidifying its position as a key player in the CNS market.

DitchCarbon Score

How does Neuraxpharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

28

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

33

Industry Benchmark

Neuraxpharm's score of 28 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.

49%

Let us know if this data was useful to you

Neuraxpharm's reported carbon emissions

In 2025, Neuraxpharm reported total carbon emissions of approximately 917,000 kg CO2e, comprising 66,000 kg CO2e from Scope 2 and 851,000 kg CO2e from Scope 3 emissions. The previous year, 2024, saw emissions of about 578,000 kg CO2e, with 8,000 kg CO2e from Scope 2 and 570,000 kg CO2e from Scope 3. In 2023, the company recorded around 454,000 kg CO2e, including 1,000 kg CO2e from Scope 2 and 453,000 kg CO2e from Scope 3. Neuraxpharm's emissions data from 2022 indicates a significant contribution from Scope 1 and 2, totalling approximately 3,000,000 kg CO2e, with 1,776,150 kg CO2e from Scope 1 and 1,461,700 kg CO2e from Scope 2. The 2021 figures were about 1,138,000 kg CO2e, with 389,000 kg CO2e from Scope 1 and 749,000 kg CO2e from Scope 2. In 2020, emissions were approximately 771,000 kg CO2e, consisting of 446,000 kg CO2e from Scope 2 and 325,000 kg CO2e from Scope 3. Currently, Neuraxpharm has not set any specific reduction targets or initiatives, nor do they participate in the Science Based Targets initiative (SBTi). The company does not inherit emissions data from any parent organisation, indicating that all reported figures are self-generated.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

202020212022202320242025
Scope 1
-
000,000
0,000,000
-
-
-
Scope 2
446,000
000,000
0,000,000
0,000
0,000
00,000
Scope 3
325,000
-
-
000,000
000,000
000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Neuraxpharm's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Neuraxpharm is in ES, which has a very high grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Neuraxpharm is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Glaxosmithkline

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 15 hours ago

Viatris

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 hours ago

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated about 22 hours ago

Boehringer Ingelheim Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

STADA Arzneimittel Aktiengesellschaft

DE
•
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251020.1
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy